Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15786419 | 0.87 | RXRA (0.39) | KCNN4NOTUMLRRK2RXRAGRIN1 | |
| SCHEMBL428154 | 0.85 | KCNN4 (0.32) | KCNN4 | |
| SCHEMBL430614 | 0.83 | MAP3K5 (0.35) | — | |
| SCHEMBL18066911 | 0.82 | KCNN4 (0.38) | KCNN4NOTUMLRRK2RXRAGRIN1 | |
| SCHEMBL15783479 | 0.82 | NOTUM (0.35) | NOTUMLRRK2RXRAGRIN1GRIN2B | |
| SCHEMBL10199221 | 0.82 | KCNN4 (0.30) | KCNN4 | |
| SCHEMBL18995070 | 0.82 | ALDH1A1 (0.32) | NOTUMLRRK2 | |
| SCHEMBL431151 | 0.79 | ALDH1A1 (0.39) | — | |
| SCHEMBL19527528 | 0.78 | SMURF1 (0.42) | NOTUM | |
| SCHEMBL15790816 | 0.76 | LRRK2 (0.43) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10792282-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-2595982-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-20170360786-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360786-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20140275055-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2014-09-18 | — | — | US | disclosed |
| US-8710223-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710223-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710223-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2595982-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2012-01-26 | — | — | US | disclosed |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2012-01-26 | — | — | US | disclosed |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2012-01-26 | — | — | US | disclosed |
| WO-2012012619-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012619-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360786-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | KCNN4 4146/4885NOTUM 1505/4885LRRK2 391/4885 |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | KCNN4 4146/4885NOTUM 1505/4885LRRK2 391/4885 |
| US-20140275055-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | KCNN4 4146/4885NOTUM 1505/4885LRRK2 391/4885 |
| US-10792282-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | KCNN4 4146/4885NOTUM 1505/4885LRRK2 391/4885 |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | KCNN4 4146/4885NOTUM 1505/4885LRRK2 391/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | KCNN4 4146/4885NOTUM 1505/4885LRRK2 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.